Teriparatide: Evidence, Mechanism, Dosing & Legal Status

Teriparatide (Forteo, PTH 1-34) is the biologically active N-terminal fragment of parathyroid hormone, produced by recombinant DNA technology in E. coli and marketed by Eli Lilly. It was FDA-approved in November 2002 as the first bone-building — as opposed to bone-preserving — osteoporosis therapy.15 Unlike most compounds in the peptide-recovery conversation, teriparatide has a deep, completed human randomized-trial base. This monograph separates what is proven from what is extrapolated.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Teriparatide is a prescription drug; decisions about osteoporosis or fracture therapy must be made with a qualified clinician. Dosing figures are reported strictly as seen in the published literature and FDA labeling for completeness — not as recommendations.

What is teriparatide and how does it work?

Teriparatide is the first 34 N-terminal amino acids of the 84-residue human parathyroid hormone — the segment that activates the PTH-1 receptor (PTH1R). Its molecular formula is C₁₈₁H₂₉₁N₅₅O₅₁S₂ with a molecular weight of about 4,118 g/mol.15 The defining pharmacologic insight is dose-timing-dependent biology: intermittent once-daily exposure is net anabolic (bone-forming), whereas continuous exposure — as in primary hyperparathyroidism or a continuous infusion — is net catabolic (bone-resorbing).7

The once-daily subcutaneous injection produces a sharp, transient PTH1R activation that preferentially drives the cAMP/PKA/CREB cascade favoring osteoblast differentiation and survival, before returning to baseline too quickly to sustain the RANKL upregulation that would drive osteoclastogenesis.8 Mechanistically, teriparatide increases osteoblast number and activity chiefly through an anti-apoptotic effect (prolonged osteoblast survival) and by reactivating quiescent bone-lining cells; it activates canonical Wnt/β-catenin signaling, partly by suppressing osteocyte secretion of the bone-formation inhibitor sclerostin, and raises local IGF-1.8 Because formation and resorption are coupled, each remodeling unit ends in a positive bone balance, with an early 'anabolic window' of formation outpacing resorption; the bone-formation marker P1NP rises within 1–3 months and is used clinically to confirm response.9 Subcutaneous bioavailability is about 95%, peak serum concentration occurs roughly 30 minutes after injection, and serum half-life is about one hour — the brief exposure is the mechanism.15

What is the evidence by indication?

Teriparatide's evidence is anchored by two large fracture-endpoint randomized trials. In the pivotal Fracture Prevention Trial, 1,637 postmenopausal women with prior vertebral fractures were randomized to placebo or teriparatide (20 µg or 40 µg daily) for a median of about 19–21 months; new vertebral fractures fell from 14% on placebo to 5% on 20 µg (RR 0.35), and nonvertebral fragility fractures fell from 6% to 3%.1 The full registry record for the broader teriparatide program can be reviewed at ClinicalTrials.gov. The active-comparator VERO trial then randomized 1,360 women with severe osteoporosis to teriparatide versus oral risedronate over 24 months: new vertebral fractures were 5.4% versus 12.0% (RR 0.44, p<0.0001) and clinical fractures 4.8% versus 9.8% — the first head-to-head proof that an anabolic agent beats an antiresorptive on fracture endpoints.2 Subgroup analyses confirmed consistency across age, BMD, and fracture-history strata, and meta-analyses favor teriparatide over alendronate.314

Teriparatide is also FDA-approved for glucocorticoid-induced osteoporosis, where head-to-head data show it superior to alendronate on spine BMD and vertebral-fracture reduction, and for increasing bone mass in men with primary or hypogonadal osteoporosis on BMD-endpoint trials.1516 The most-extrapolated indication — and the one most relevant to bone-healing content — is off-label fracture healing, and it must be framed honestly. A meta-analysis of 5 RCTs (n=380) found teriparatide can shorten time to union at the 20 µg dose, and a hip-fracture meta-analysis (n=607) found it reduced time to union by about two weeks (WMD −1.95 weeks, p=0.003) — but that same analysis found no improvement in union rates at 3 or 6 months and no reduction in reoperation or mortality.1011 A 2023 systematic review of 32 mostly-case-series reports concluded teriparatide is safe and useful for inducing callus, but the high-quality base is thin.1213

What doses appear in the literature?

Reported strictly as information, not a protocol. The marketed and clinical dose is 20 µg subcutaneously once daily, delivered by a prefilled multi-dose pen and injected into the thigh or abdominal wall; first doses are given where the patient can sit or lie down because of early orthostatic risk.4 The Fracture Prevention Trial tested 20 µg and 40 µg, but 40 µg gave more BMD with more adverse effects and no added fracture benefit, so 20 µg is standard.1 Duration was historically capped at 24 months lifetime; the FDA removed that limit in November 2020, so duration is now individualized to fracture risk and BMD response.6 Because BMD gains are lost after stopping, an antiresorptive (bisphosphonate or denosumab) is typically given afterward in a widely used 'anabolic-first, then antiresorptive' sequence; trials co-administered calcium and vitamin D.9 The product is a refrigerated pen, supplied as 600 µg/2.4 mL for 28 days of clinical use.19

How safe is teriparatide?

The common adverse events from RCTs are well characterized: transient hypercalcemia (about 11% of patients in the pivotal trial, largely self-resolving), nausea, headache, dizziness, leg cramps, orthostatic hypotension after the first few doses, injection-site reactions, and mild hyperuricemia.17 The central historical concern was osteosarcoma: lifetime, high-dose rat studies showed dose- and duration-dependent osteosarcoma, prompting the original boxed warning and 2-year cap. Across 18 years of human post-marketing surveillance — including large claims-linked cohort studies cross-referenced with cancer registries — no increased osteosarcoma incidence was observed, so the FDA removed the boxed warning and the 2-year limit on November 16, 2020, a model of evidence-driven de-risking.45

Because of that historical signal, teriparatide is contraindicated or used with caution in populations with elevated baseline bone-tumor risk or bone turnover: Paget's disease of bone; open epiphyses (children and young adults with a growing skeleton); prior skeletal radiation; bone metastases or skeletal malignancy; hereditary metabolic bone disorders; and pre-existing hypercalcemia or primary hyperparathyroidism. Caution also applies in active urolithiasis given the calcium effects, and with digoxin (hypercalcemia can predispose to digitalis toxicity).1516 It is not indicated in pregnancy or lactation. Notably, the osteosarcoma question is the only tumor concern here with a real mechanistic basis, and human data have not borne it out — there is no credible angiogenesis-driven cancer signal in the human literature.4

What is the FDA and WADA status in 2026?

Teriparatide is an FDA-approved prescription drug — Forteo (Eli Lilly), approved November 2002 for osteoporosis at high fracture risk, with the boxed osteosarcoma warning and 2-year lifetime limit removed effective November 16, 2020.45 Brand exclusivity lapsed in 2019; a 505(b)(2) follow-on (PF708/Bonsity) was approved in October 2019, EU biosimilars (Qutavina, Livogiva, Sondelbay, Movymia) followed from 2020, and a substitutable generic teriparatide reached the US market around November 2023.1718 As an FDA-approved commercial product it is normally dispensed as the manufactured pen rather than compounded, so no 503A Category-2 bulk-substance controversy comparable to the unapproved research peptides applies. It is not a DEA controlled substance.15

For athletes, teriparatide is not specifically named on the WADA Prohibited List and has no demonstrated performance-enhancing effect in healthy adults — its action is on bone remodeling, not muscle or endurance. As a peptide hormone, athletes should still verify current status on GlobalDRO by brand and ingredient and, if treating genuine osteoporosis, consider a Therapeutic Use Exemption, since strict-liability rules apply.2021 Branded Forteo historically cost more than $5,000 per pen; biosimilars and generics price roughly 20–40%+ lower.19

Bottom line. Teriparatide is among the best-validated peptide drugs in this field — a genuine, FDA-approved bone-anabolic hormone with Grade A RCT evidence for reducing vertebral and nonvertebral fractures in high-risk osteoporosis, and proven superior to a standard antiresorptive on fracture endpoints. The honest caveats for a bone-healing audience: its proven benefit is fracture prevention, not acute fracture healing; for off-label fracture-healing use the evidence is Grade B at best and unproven for hard union rates; and it is a costly, refrigerated, daily self-injected prescription biologic, not a casually obtained research peptide. Verdict: proven and important within osteoporosis, promising-but-unproven for accelerating fracture healing, and not a performance agent.